Article
Biochemistry & Molecular Biology
Shaimaa Hamza, Ekaterina E. E. Garanina, Mohammad Alsaadi, Svetlana F. F. Khaiboullina, Gulcin Tezcan
Summary: NLRP3 may contribute to the growth and propagation of breast cancer, and the effects of ER-alpha, PR, and HER2 on NLRP3 activation in breast cancer are still unknown.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Eugene F. Schuster, Elena Lopez-Knowles, Anastasia Alataki, Lila Zabaglo, Elizabeth Folkerd, David Evans, Kally Sidhu, Maggie Chon U. Cheang, Holly Tovey, Manuel Salto-Tellez, Perry Maxwell, John Robertson, Ian Smith, Judith M. Bliss, Mitch Dowsett
Summary: This study conducts a large-scale molecular analysis to compare the response of ER + HER2- breast cancer patients to aromatase inhibitors (AIs). It identifies low ESR1 levels as a predictor for poor response, with high proliferation, expression of growth factor pathways, and non-luminal subtypes. Additionally, it indicates that patients with high ESR1 expression have similar proportions of luminal subtypes to good responders, but lower plasma estradiol levels, lower expression of estrogen response genes, higher levels of tumor infiltrating lymphocytes and immune markers, and more TP53 mutations.
NATURE COMMUNICATIONS
(2023)
Article
Biochemistry & Molecular Biology
Alok Mishra, Anshuman Srivastava, Ankit Pateriya, Manendra Singh Tomar, Anand Kumar Mishra, Ashutosh Shrivastava
Summary: Breast cancer is the most common cancer among females, and endocrine therapy for ER-positive breast cancer can result in acquired resistance. The metabolic state of cancer cells plays a crucial role in their susceptibility to chemotherapeutic drugs, and understanding metabolic pathway alterations in TAMR cancer may offer potential therapeutic strategies.
CHEMICO-BIOLOGICAL INTERACTIONS
(2021)
Article
Medicine, Research & Experimental
Sheila Almaraz Postigo, Juan Carlos Montero
Summary: In this study, the researchers found that Neuregulins (NRGs) regulate estrogen receptor α (ERα) in breast cancer cells through multiple mechanisms. NRGs activate the PI3K/AKT/mTOR, ERK1/2, and ERK5 pathways, leading to phosphorylation of ERα and down-regulation of its expression. NRGs also confer resistance to fulvestrant in breast cancer cells. However, this resistance can be reversed by simultaneously inhibiting these three pathways.
Article
Oncology
Iris Noordhoek, Kai Treuner, Hein Putter, Yi Zhang, Jenna Wong, Elma Meershoek-Klein Kranenbarg, Marjolijn Duijm-de Carpentier, Cornelis J. H. van de Velde, Catherine A. Schnabel, Gerrit-Jan Liefers
Summary: This study found that BCI (H/I) as a biomarker could predict the benefit of extended endocrine therapy in patients with early-stage HR+ breast cancer, providing important clinical implications for treatment decisions.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Stephen R. D. Johnston, Masakazu Toi, Joyce O'Shaughnessy, Priya Rastogi, Mario Campone, Patrick Neven, Chiun-Sheng Huang, Jens Huober, Georgina Garnica Jaliffe, Irfan Cicin, Sara M. Tolaney, Matthew P. Goetz, Hope S. Rugo, Elzbieta Senkus, Laura Testa, Lucia Del Mastro, Chikako Shimizu, Ran Wei, Ashwin Shahir, Maria Munoz, Belen San Antonio, Valerie Andre, Nadia Harbeck, Miguel Martin
Summary: In patients with high-risk hormone receptor-positive, HER2-negative early breast cancer, adjuvant abemaciclib plus endocrine therapy improves invasive disease-free survival and distant relapse-free survival. The benefit of abemaciclib extends beyond the completion of treatment, supporting its use in this patient population.
Article
Medicine, General & Internal
Timothy J. Whelan, Sally Smith, Sameer Parpia, Anthony W. Fyles, Anita Bane, Fei-Fei Liu, Eileen Rakovitch, Lynn Chang, Christiaan Stevens, Julie Bowen, Sawyna Provencher, Valerie Theberge, Anna Marie Mulligan, Zuzana Kos, Mohamed A. Akra, K. David Voduc, Tarek Hijal, Ian S. Dayes, Gregory Pond, James R. Wright, Torsten O. Nielsen, Mark N. Levine
Summary: Among women with T1N0 grade 1 or 2 luminal A breast cancer who had undergone breast-conserving surgery and received endocrine therapy, the incidence of local recurrence at 5 years was low without radiotherapy.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Nivida Shete, Jordan Calabrese, Debra A. Tonetti
Summary: Estrogen is a key driver of estrogen-receptor-positive breast cancers, and drugs that block estrogen signaling are commonly used for treatment. Surprisingly, estrogen was previously used to treat breast cancer before the introduction of tamoxifen. This review focuses on the insights, molecular mechanisms, and potential clinical application of this counterintuitive therapeutic approach.
Article
Oncology
John M. S. Bartlett, Dennis C. Sgroi, Kai Treuner, Yi Zhang, Tammy Piper, Ranelle C. Salunga, Ikhlaaq Ahmed, Lucy Doos, Sarah Thornber, Karen J. Taylor, Elena F. Brachtel, Sarah J. Pirrie, Catherine A. Schnabel, Daniel W. Rea
Summary: The study found that BCI (H/I) can significantly predict the benefit of extended tamoxifen therapy in HR+ N+ HER2(-) early-stage breast cancer patients. Moreover, BCI (H/I) demonstrates significant treatment to biomarker interaction across survival outcomes.
CLINICAL CANCER RESEARCH
(2022)
Article
Medicine, Research & Experimental
Coralie Poulard, Thuy Ha Pham, Youenn Drouet, Julien Jacquemetton, Ausra Surmielova, Loay Kassem, Benoite Mery, Christine Lasset, Jonathan Reboulet, Isabelle Treilleux, Elisabetta Marangoni, Olivier Tredan, Muriel Le Romancer
Summary: Endocrine therapies targeting estrogen signaling have improved management of estrogen receptor alpha (ERα)-positive breast cancers. However, resistance to treatment remains a challenge. This study identifies nuclear PRMT5 expression as a predictive marker of sensitivity to tamoxifen in breast cancer patients, and reveals the mechanism of tamoxifen stimulating ERα methylation by PRMT5. This biomarker could be used to enhance response to tamoxifen in ERα-positive breast tumors.
EMBO MOLECULAR MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Ying Liang, Qi Lu, Wei Li, Dapeng Zhang, Fanglin Zhang, Qingping Zou, Lu Chen, Ying Tong, Mengxing Liu, Shaoxuan Wang, Wenxuan Li, Xiaoguang Ren, Peng Xu, Zhicong Yang, Shihua Dong, Baolong Zhang, Yanni Huang, Daqiang Li, Hailin Wang, Wenqiang Yu
Summary: Dysfunction of Tumour Suppressor Genes (TSGs) is common in carcinogenesis, with low expression of miRNA potentially reducing TSG activity through enhancer regulation. In breast cancer, downregulation of GPER1 and miR-339 is observed, with mechanistic investigations revealing the role of miR-339 in upregulating GPER1 expression through enhancer switching. This highlights a potential alternative strategy for breast cancer treatment through reactivation of TSGs by enhancer manipulation.
NUCLEIC ACIDS RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Faten Shehadeh-Tout, Heloisa H. Milioli, Suraya Roslan, Patric J. Jansson, Mahendiran Dharmasivam, Dinny Graham, Robin Anderson, Tharushi Wijesinghe, Mahan Gholam Azad, Des R. Richardson, Zaklina Kovacevic
Summary: This study investigates a new class of anti-cancer agents for the treatment of ER-positive breast cancer. These agents inhibit multiple growth factor receptors and down-stream signaling, leading to decreased expression of hormone receptors and key resistance pathways. In vivo experiments demonstrate that these agents effectively inhibit ER-positive breast cancer growth. This represents an innovative non-hormonal, multi-modal therapeutic approach.
PHARMACOLOGICAL RESEARCH
(2023)
Article
Oncology
Lindsay J. Collin, Maret L. Maliniak, Deirdre P. Cronin-Fenton, Thomas P. Ahern, Kristina B. Christensen, Sinna P. Ulrichsen, Per Damkier, Stephen Hamilton-Dutoit, Rami Yacoub, Peer M. Christiansen, Henrik Toft Sorensen, Timothy L. Lash
Summary: The study found that HIF-1α expression is not directly associated with overall breast cancer recurrence, but may be related to early recurrence in patients with ER-negative breast cancer.
BREAST CANCER RESEARCH
(2021)
Article
Oncology
Takuji Iwase, Shigehira Saji, Kotaro Iijima, Kenji Higaki, Shoichiro Ohtani, Yasuyuki Sato, Yasuo Hozumi, Yoshie Hasegawa, Yasuhiro Yanagita, Hiroyuki Takei, Maki Tanaka, Hideji Masuoka, Masahiko Tanabe, Chiyomi Egawa, Yoshifumi Komoike, Toshitaka Nakamura, Hiroshi Ohtsu, Hirofumi Mukai
Summary: This study investigated the effects of extending the treatment with an aromatase inhibitor for 10 years on disease-free survival in postmenopausal hormone receptor-positive breast cancer patients. The results showed that extending the treatment with an aromatase inhibitor for an additional 5 years improved disease-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Tom van den Bosch, Oscar M. Rueda, Carlos Caldas, Louis Vermeulen, Daniel M. Miedema
Summary: This study found that low-risk breast cancer patients identified using chromosomal copy-number ITH do not benefit from adjuvant endocrine therapy.
BRITISH JOURNAL OF CANCER
(2022)
